CL2012000196A1 - Uso del éster metílico del ácido (2r,3r)-2-(3-carbamimidoil-bencil)-3-[4-(1-oxi-piridin-4-il)benzoilamino]-butírico (otamixaban) en el tratamiento del infarto al miocardio sin elevación del st y concomitante con insuficiencia renal. - Google Patents
Uso del éster metílico del ácido (2r,3r)-2-(3-carbamimidoil-bencil)-3-[4-(1-oxi-piridin-4-il)benzoilamino]-butírico (otamixaban) en el tratamiento del infarto al miocardio sin elevación del st y concomitante con insuficiencia renal.Info
- Publication number
- CL2012000196A1 CL2012000196A1 CL2012000196A CL2012000196A CL2012000196A1 CL 2012000196 A1 CL2012000196 A1 CL 2012000196A1 CL 2012000196 A CL2012000196 A CL 2012000196A CL 2012000196 A CL2012000196 A CL 2012000196A CL 2012000196 A1 CL2012000196 A1 CL 2012000196A1
- Authority
- CL
- Chile
- Prior art keywords
- otamixaban
- carbamimidoyl
- benzoylamino
- myocardium
- concomitant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso del éster metílico del ácido (2R,3R)-2-(3-carbamimidoil-bencil)-3-[4-(1-oxi-piridin-4-il)benzoilamino]-butírico (otamixaban) en el tratamiento del infarto al miocardio sin elevación del ST y concomitante con insuficiencia renal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09290601 | 2009-07-29 | ||
EP10305192 | 2010-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012000196A1 true CL2012000196A1 (es) | 2012-10-05 |
Family
ID=42542846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012000196A CL2012000196A1 (es) | 2009-07-29 | 2012-01-24 | Uso del éster metílico del ácido (2r,3r)-2-(3-carbamimidoil-bencil)-3-[4-(1-oxi-piridin-4-il)benzoilamino]-butírico (otamixaban) en el tratamiento del infarto al miocardio sin elevación del st y concomitante con insuficiencia renal. |
Country Status (25)
Country | Link |
---|---|
US (1) | US9492437B2 (es) |
EP (1) | EP2459193A1 (es) |
JP (1) | JP2013500298A (es) |
KR (1) | KR20120038982A (es) |
CN (1) | CN102470128A (es) |
AR (1) | AR077427A1 (es) |
AU (1) | AU2010277725B2 (es) |
BR (1) | BR112012001900A2 (es) |
CA (1) | CA2766533A1 (es) |
CL (1) | CL2012000196A1 (es) |
CO (1) | CO6491041A2 (es) |
CR (1) | CR20110674A (es) |
DO (1) | DOP2012000012A (es) |
EC (1) | ECSP12011627A (es) |
IL (1) | IL217612A (es) |
MA (1) | MA33455B1 (es) |
MX (1) | MX2012000457A (es) |
NI (1) | NI201200008A (es) |
NZ (1) | NZ597957A (es) |
PE (1) | PE20121401A1 (es) |
RU (1) | RU2542455C2 (es) |
SG (1) | SG177772A1 (es) |
TW (1) | TWI463982B (es) |
UY (1) | UY32807A (es) |
WO (1) | WO2011012527A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2597423C2 (ru) * | 2011-03-29 | 2016-09-10 | Санофи | Бензойнокислая соль отамиксабана |
TWI551289B (zh) * | 2011-03-29 | 2016-10-01 | 賽諾菲公司 | 具有改良之安定性之奧米沙班調配物 |
AU2012234323A1 (en) | 2011-03-29 | 2013-10-17 | Sanofi | Otamixaban formulations with improved stability |
CA2883625A1 (en) * | 2012-08-31 | 2014-03-06 | Sanofi | Otamixaban for use in the treatment of non-st elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1273128C (zh) * | 1996-01-02 | 2006-09-06 | 阿温蒂斯药物公司 | 取代的n-[(氨基亚氨基甲基或氨基甲基)苯基]丙基酰胺 |
RU2225617C1 (ru) * | 2002-12-16 | 2004-03-10 | Научно-исследовательский институт кардиологии Томского научного центра СО РАМН | Способ определения дифференцированного назначения гепаринов больным с острым коронарным синдромом без подъема сегмента st |
-
2010
- 2010-07-22 JP JP2012522112A patent/JP2013500298A/ja active Pending
- 2010-07-22 CA CA2766533A patent/CA2766533A1/en not_active Abandoned
- 2010-07-22 WO PCT/EP2010/060615 patent/WO2011012527A1/en active Application Filing
- 2010-07-22 RU RU2012107483/15A patent/RU2542455C2/ru not_active IP Right Cessation
- 2010-07-22 PE PE2012000036A patent/PE20121401A1/es not_active Application Discontinuation
- 2010-07-22 MA MA34566A patent/MA33455B1/fr unknown
- 2010-07-22 BR BR112012001900A patent/BR112012001900A2/pt not_active IP Right Cessation
- 2010-07-22 MX MX2012000457A patent/MX2012000457A/es active IP Right Grant
- 2010-07-22 KR KR1020127002078A patent/KR20120038982A/ko not_active Application Discontinuation
- 2010-07-22 NZ NZ597957A patent/NZ597957A/en not_active IP Right Cessation
- 2010-07-22 CN CN2010800323309A patent/CN102470128A/zh active Pending
- 2010-07-22 AU AU2010277725A patent/AU2010277725B2/en not_active Ceased
- 2010-07-22 US US13/387,639 patent/US9492437B2/en not_active Expired - Fee Related
- 2010-07-22 EP EP10735284A patent/EP2459193A1/en not_active Withdrawn
- 2010-07-22 SG SG2012006110A patent/SG177772A1/en unknown
- 2010-07-27 TW TW099124612A patent/TWI463982B/zh not_active IP Right Cessation
- 2010-07-27 AR ARP100102707A patent/AR077427A1/es unknown
- 2010-07-27 UY UY0001032807A patent/UY32807A/es not_active Application Discontinuation
-
2011
- 2011-12-15 CR CR20110674A patent/CR20110674A/es unknown
-
2012
- 2012-01-12 NI NI201200008A patent/NI201200008A/es unknown
- 2012-01-16 CO CO12005490A patent/CO6491041A2/es not_active Application Discontinuation
- 2012-01-18 IL IL217612A patent/IL217612A/en not_active IP Right Cessation
- 2012-01-19 DO DO2012000012A patent/DOP2012000012A/es unknown
- 2012-01-24 CL CL2012000196A patent/CL2012000196A1/es unknown
- 2012-01-26 EC EC2012011627A patent/ECSP12011627A/es unknown
Also Published As
Publication number | Publication date |
---|---|
NZ597957A (en) | 2014-05-30 |
BR112012001900A2 (pt) | 2016-03-15 |
WO2011012527A1 (en) | 2011-02-03 |
KR20120038982A (ko) | 2012-04-24 |
AU2010277725A1 (en) | 2012-02-16 |
IL217612A (en) | 2014-08-31 |
NI201200008A (es) | 2012-05-29 |
CN102470128A (zh) | 2012-05-23 |
TWI463982B (zh) | 2014-12-11 |
CR20110674A (es) | 2012-04-17 |
AR077427A1 (es) | 2011-08-24 |
AU2010277725B2 (en) | 2016-08-18 |
JP2013500298A (ja) | 2013-01-07 |
PE20121401A1 (es) | 2012-10-25 |
US9492437B2 (en) | 2016-11-15 |
DOP2012000012A (es) | 2012-02-15 |
MX2012000457A (es) | 2012-01-27 |
SG177772A1 (en) | 2012-03-29 |
RU2542455C2 (ru) | 2015-02-20 |
MA33455B1 (fr) | 2012-07-03 |
EP2459193A1 (en) | 2012-06-06 |
TW201119655A (en) | 2011-06-16 |
UY32807A (es) | 2011-02-28 |
CO6491041A2 (es) | 2012-07-31 |
ECSP12011627A (es) | 2012-02-29 |
RU2012107483A (ru) | 2013-09-10 |
US20120238605A1 (en) | 2012-09-20 |
CA2766533A1 (en) | 2011-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120646T1 (el) | Προγονικα κυτταρα μεσοδερμικης προελευσης | |
CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
EA201270619A1 (ru) | Применение бетанехола для лечения ксеростомии | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
CL2013000104A1 (es) | Compuestos derivados de heterociclicos nitrogenados sustituidos, agonistas del receptor ip; composicion farmaceutica; combinación farmaceutica; y uso para el tratamiento de la hipertension arterial pulmonar. | |
IT1399435B1 (it) | Anta per mobili con pannello amovibile - intercambiabile. | |
EA201490070A1 (ru) | Коантагонисты глюкагонового рецептора/glp-1-рецептора | |
EA201590807A1 (ru) | Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций | |
EA201391764A1 (ru) | Агонисты рецептора glp-1/глюкагона длительного действия | |
CL2013000603A1 (es) | Compuestos derivados de quinolina y quinoxalina, inhibidores pi3k; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria, autoinmune, cardiovascular, neurodegenerativa, metabolica, oncologica, nocicenociceptiva y oftalmica. | |
BR112014030064A2 (pt) | composição do ácido carboxílico. | |
BR112015001487A2 (pt) | composição detergente líquida alcalina concentrada | |
UY34200A (es) | 3-(fluorovinil)pirazoles y su uso | |
UA113620C2 (xx) | Композиція, що містить аморфну (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)оцтову кислоту | |
EA201390799A1 (ru) | Триазолопиридины | |
DK2858986T3 (da) | Piperidinderivater som gpr119-agonister | |
CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
TR201905787T4 (tr) | Liyofilize TAT-NR2B9C formülasyonu. | |
CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
UY34629A (es) | Inhibidores de pirazolopirimidinilo de enzima activadora de ubicuitina | |
MX347373B (es) | Soluciones anti-inflamatorias estables para inyección. | |
EA201300733A1 (ru) | Рекомбинантные микобактерии в качестве вакцины | |
CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
CL2012000196A1 (es) | Uso del éster metílico del ácido (2r,3r)-2-(3-carbamimidoil-bencil)-3-[4-(1-oxi-piridin-4-il)benzoilamino]-butírico (otamixaban) en el tratamiento del infarto al miocardio sin elevación del st y concomitante con insuficiencia renal. | |
MX358132B (es) | Solucion de trombina y metodos de uso de esta. |